38 Works

Additional file 1 of Chromosome-level assemblies from diverse clades reveal limited structural and gene content variation in the genome of Candida glabrata

Marina Marcet-Houben, María Alvarado, Ewa Ksiezopolska, Ester Saus, Piet W. J. de Groot & Toni Gabaldón
Additional file 1: Fig S1. Comparison of reference assemblies. Fig S2. Circos plots representing structural variation among strains. Fig S3. Dotplot representing improvements in assembly of strain CAS08-0016. Fig S4. Barplot representing origin of accessory families. Fig S5. Graphical representation of the adhesin detection pipeline. Fig S6. Gains and losses of adhesin families in the C. glabrata strains. Fig S7. Summary of the LongHam pipeline. Fig S8. Example of an adhesin gene cluster. Fig S9....

Integrative pathway enrichment analysis of multivariate omics data

Marta Paczkowska, Jonathan Barenboim, Nardnisa Sintupisut, Natalie S Fox, Helen Zhu, Diala Abd-Rabbo, Miles W Mee, Paul C Boutros, Federico Abascal, Samirkumar B Amin, Gary D Bader, Rameen Beroukhim, Johanna Bertl, Keith A Boroevich, Søren Brunak, Peter J Campbell, Joana Carlevaro-Fita, Dimple Chakravarty, Calvin Wing Yiu Chan, Ken Chen, Jung Kyoon Choi, Jordi Deu-Pons, Priyanka Dhingra, Klev Diamanti, Lars Feuerbach … & L van’t Veer
Multi-omics datasets represent distinct aspects of the central dogma of molecular biology. Such high-dimensional molecular profiles pose challenges to data interpretation and hypothesis generation. ActivePathways is an integrative method that discovers significantly enriched pathways across multiple datasets using statistical data fusion, rationalizes contributing evidence and highlights associated genes. As part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658 cancers across 38 tumor types, we integrated...

Additional file 3 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 3: Figure S3. LAMC2 expression correlates with CSC content and function. (a) qPCR analysis of LAMC2 gene expression in adherent cells versus spheres. Data are normalized to GAPDH and are presented as fold change in gene expression relative to adherent cells (indicated as Adh). (b) Western blot analysis of LAMC2 in adherent cells versus spheres. Parallel β-ACTIN immunoblotting was performed. (c) qPCR analysis for CD44, CD133 and L1CAM genes in adherent cells versus...

Additional file 9 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 9: Figure S9. Global gene expression profiles of LAMC2-EGFP+ and EGFP--derived tumors. Heat map of differentially expressed genes in EGFP+ and EGFP- cells isolated from tumors.

Additional file 7 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 7: Figure S7. Generation of LAMC2-EGFP knock-in human PDAC cells. (a) Flow cytometry for IRFP in PDAC cells 48 hours post-nucleofection. All cytometry gates were established based on isotype controls. (b) Flow cytometry for EGFP in PDAC cells 20 days post-nucleofection. All cytometry gates were established based on isotype controls. (c) PCR gDNA specific integration analysis. The positions of primers are indicated by arrows. (d) FACS profiles showing the expression of EGFP in...

Additional file 8 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 8: Figure S8. Characterization of human LAMC2-EGFP PDAC cells in vitro and in vivo. (a) Representative images of EGFP+ and EGFP-cells grown in Matrigel. (b) Organoid formation capacity of EGFP+ and EGFP-cells. (c) Quantification of organoid size of EGFP+ and EGFP-cells. (d) qPCR analysis for LAMC2, EMT, MMP2 and MMP10 gene expression in EGFP+ and EGFP-cells. Data are normalized to GAPDH and are presented as fold change in gene expression relative to the...

Divergent mutational processes distinguish hypoxic and normoxic tumours

Vinayak Bhandari, Constance H Li, Robert G Bristow, Paul C Boutros, Lauri A Aaltonen, Federico Abascal, Adam Abeshouse, Hiroyuki Aburatani, David J Adams, Nishant Agrawal, Keun Soo Ahn, Sung-Min Ahn, Hiroshi Aikata, Rehan Akbani, Kadir C Akdemir, Hikmat Al-Ahmadie, Sultan T Al-Sedairy, Fatima Al-Shahrour, Malik Alawi, Monique Albert, Kenneth Aldape, Ludmil B Alexandrov, Adrian Ally, Kathryn Alsop, Eva G Alvarez … & Christian von Mering
Many primary tumours have low levels of molecular oxygen (hypoxia), and hypoxic tumours respond poorly to therapy. Pan-cancer molecular hallmarks of tumour hypoxia remain poorly understood, with limited comprehension of its associations with specific mutational processes, non-coding driver genes and evolutionary features. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658 cancers across 38 tumour types, we quantify hypoxia in 1188 tumours spanning...

Combined burden and functional impact tests for cancer driver discovery using DriverPower

Shimin Shuai, Federico Abascal, Samirkumar B Amin, Gary D Bader, Pratiti Bandopadhayay, Jonathan Barenboim, Rameen Beroukhim, Johanna Bertl, Keith A Boroevich, Søren Brunak, Peter J Campbell, Joana Carlevaro-Fita, Dimple Chakravarty, Calvin Wing Yiu Chan, Ken Chen, Jung Kyoon Choi, Jordi Deu-Pons, Priyanka Dhingra, Klev Diamanti, Lars Feuerbach, J Lynn Fink, Nuno A Fonseca, Joan Frigola, Carlo Gambacorti-Passerini, Dale W Garsed … & L van’t Veer
The discovery of driver mutations is one of the key motivations for cancer genome sequencing. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658 cancers across 38 tumour types, we describe DriverPower, a software package that uses mutational burden and functional impact evidence to identify driver mutations in coding and non-coding sites within cancer whole genomes. Using a total of 1373 genomic features...

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Wei Jiao, Gurnit Atwal, Paz Polak, Rosa Karlic, Edwin Cuppen, Fatima Al-Shahrour, Peter J Bailey, Andrew V Biankin, Paul C Boutros, Peter J Campbell, David K Chang, Susanna L Cooke, Vikram Deshpande, Bishoy M Faltas, William C Faquin, Levi Garraway, Gad Getz, Sean M Grimmond, Syed Haider, Katherine A Hoadley, Vera B Kaiser, Mamoru Kato, Kirsten Kübler, Alexander J Lazar, Constance H Li … & Christian von Mering
In cancer, the primary tumour’s organ of origin and histopathology are the strongest determinants of its clinical behaviour, but in 3% of cases a patient presents with a metastatic tumour and no obvious primary. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, we train a deep learning classifier to predict cancer type based on patterns of somatic passenger mutations detected in whole genome sequencing (WGS) of 2606 tumours representing 24...

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Wei Jiao, Gurnit Atwal, Paz Polak, Rosa Karlic, Edwin Cuppen, Fatima Al-Shahrour, Peter J Bailey, Andrew V Biankin, Paul C Boutros, Peter J Campbell, David K Chang, Susanna L Cooke, Vikram Deshpande, Bishoy M Faltas, William C Faquin, Levi Garraway, Gad Getz, Sean M Grimmond, Syed Haider, Katherine A Hoadley, Vera B Kaiser, Mamoru Kato, Kirsten Kübler, Alexander J Lazar, Constance H Li … & Christian von Mering
In cancer, the primary tumour’s organ of origin and histopathology are the strongest determinants of its clinical behaviour, but in 3% of cases a patient presents with a metastatic tumour and no obvious primary. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, we train a deep learning classifier to predict cancer type based on patterns of somatic passenger mutations detected in whole genome sequencing (WGS) of 2606 tumours representing 24...

Additional file 3 of Chromosome-level assemblies from diverse clades reveal limited structural and gene content variation in the genome of Candida glabrata

Marina Marcet-Houben, María Alvarado, Ewa Ksiezopolska, Ester Saus, Piet W. J. de Groot & Toni Gabaldón
Additional file 3. Chromosome-level assemblies from diverse clades reveal limited structural and gene content variation in the genome of Candida glabrata.

Additional file 3 of Chromosome-level assemblies from diverse clades reveal limited structural and gene content variation in the genome of Candida glabrata

Marina Marcet-Houben, María Alvarado, Ewa Ksiezopolska, Ester Saus, Piet W. J. de Groot & Toni Gabaldón
Additional file 3. Chromosome-level assemblies from diverse clades reveal limited structural and gene content variation in the genome of Candida glabrata.

Additional file 10 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 10: Figure S10. Inhibition of transforming growth factor beta (TGF-β) signaling blocks LAMC2-induced metastasis. (a) Enrichment plots for pancreatic cancer, focal adhesion, hypoxia, MAPK signaling, glycolysis and gluconeogenesis pathways in EGFP+ versus EGFP- cells isolated by FACS from subcutaneous tumors. (b) Western blot analysis for pSMAD2 and SMAD2 in EGFP- versus EGFP+ PANC-1 and #253 cells. Parallel GAPDH immunoblotting was performed. (c) Flow cytometry quantification of EGFP and ALK5-TGFβR1 in EGFP- and EGFP+...

Additional file 4 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 4: Figure S4. Knockdown of LAMC2 does not affect cell growth. (a) Western blot analysis of LAMC2 in sh empty and LAMC2 knockdown cells. Parallel β-ACTIN immunoblotting was performed. (b) qPCR analysis for LAMC2 and CD44 gene expression in sh empty and LAMC2 knockdown cells. Data are normalized to GAPDH and are presented as fold change in gene expression relative to sh empty. (c) Representative images of sh empty and LAMC2 knockdown cells...

Additional file 6 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 6: Figure S6. Knockdown of LAMC2 affects tumorigenicity. (a) Representative images from a gelatin degradation assay of sh empty and LAMC2 knockdown cells. Nuclei were stained with Hoechst 33342 (blue), green represents actin (Alexa Fluor™ 488 Phalloidin) and red illustrates gelatin (Rodhamine). The white dashed line circles indicate the areas of degradation. (b) Degradation potential of sh empty and LAMC2 knockdown cells. (c) qPCR analysis for EMT genes in sh empty and LAMC2...

Combined burden and functional impact tests for cancer driver discovery using DriverPower

Shimin Shuai, Federico Abascal, Samirkumar B Amin, Gary D Bader, Pratiti Bandopadhayay, Jonathan Barenboim, Rameen Beroukhim, Johanna Bertl, Keith A Boroevich, Søren Brunak, Peter J Campbell, Joana Carlevaro-Fita, Dimple Chakravarty, Calvin Wing Yiu Chan, Ken Chen, Jung Kyoon Choi, Jordi Deu-Pons, Priyanka Dhingra, Klev Diamanti, Lars Feuerbach, J Lynn Fink, Nuno A Fonseca, Joan Frigola, Carlo Gambacorti-Passerini, Dale W Garsed … & L van’t Veer
The discovery of driver mutations is one of the key motivations for cancer genome sequencing. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658 cancers across 38 tumour types, we describe DriverPower, a software package that uses mutational burden and functional impact evidence to identify driver mutations in coding and non-coding sites within cancer whole genomes. Using a total of 1373 genomic features...

Integrative pathway enrichment analysis of multivariate omics data

Marta Paczkowska, Jonathan Barenboim, Nardnisa Sintupisut, Natalie S Fox, Helen Zhu, Diala Abd-Rabbo, Miles W Mee, Paul C Boutros, Federico Abascal, Samirkumar B Amin, Gary D Bader, Rameen Beroukhim, Johanna Bertl, Keith A Boroevich, Søren Brunak, Peter J Campbell, Joana Carlevaro-Fita, Dimple Chakravarty, Calvin Wing Yiu Chan, Ken Chen, Jung Kyoon Choi, Jordi Deu-Pons, Priyanka Dhingra, Klev Diamanti, Lars Feuerbach … & L van’t Veer
Multi-omics datasets represent distinct aspects of the central dogma of molecular biology. Such high-dimensional molecular profiles pose challenges to data interpretation and hypothesis generation. ActivePathways is an integrative method that discovers significantly enriched pathways across multiple datasets using statistical data fusion, rationalizes contributing evidence and highlights associated genes. As part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658 cancers across 38 tumor types, we integrated...

Pathway and network analysis of more than 2500 whole cancer genomes

Matthew A Reyna, David Haan, Marta Paczkowska, Lieven PC Verbeke, Miguel Vazquez, Abdullah Kahraman, Sergio Pulido-Tamayo, Jonathan Barenboim, Lina Wadi, Priyanka Dhingra, Raunak Shrestha, Gad Getz, Michael S Lawrence, Jakob Skou Pedersen, Mark A Rubin, David A Wheeler, Søren Brunak, Jose MG Izarzugaza, Ekta Khurana, Kathleen Marchal, Christian von Mering, S Cenk Sahinalp, Alfonso Valencia, Federico Abascal, Samirkumar B Amin … & L van’t Veer
The catalog of cancer driver mutations in protein-coding genes has greatly expanded in the past decade. However, non-coding cancer driver mutations are less well-characterized and only a handful of recurrent non-coding mutations, most notably TERT promoter mutations, have been reported. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658 cancer across 38 tumor types, we perform multi-faceted pathway and network analyses of non-coding...

Pathway and network analysis of more than 2500 whole cancer genomes

Matthew A Reyna, David Haan, Marta Paczkowska, Lieven PC Verbeke, Miguel Vazquez, Abdullah Kahraman, Sergio Pulido-Tamayo, Jonathan Barenboim, Lina Wadi, Priyanka Dhingra, Raunak Shrestha, Gad Getz, Michael S Lawrence, Jakob Skou Pedersen, Mark A Rubin, David A Wheeler, Søren Brunak, Jose MG Izarzugaza, Ekta Khurana, Kathleen Marchal, Christian von Mering, S Cenk Sahinalp, Alfonso Valencia, Federico Abascal, Samirkumar B Amin … & L van’t Veer
The catalog of cancer driver mutations in protein-coding genes has greatly expanded in the past decade. However, non-coding cancer driver mutations are less well-characterized and only a handful of recurrent non-coding mutations, most notably TERT promoter mutations, have been reported. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658 cancer across 38 tumor types, we perform multi-faceted pathway and network analyses of non-coding...

Additional file 3 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 3: Figure S3. LAMC2 expression correlates with CSC content and function. (a) qPCR analysis of LAMC2 gene expression in adherent cells versus spheres. Data are normalized to GAPDH and are presented as fold change in gene expression relative to adherent cells (indicated as Adh). (b) Western blot analysis of LAMC2 in adherent cells versus spheres. Parallel β-ACTIN immunoblotting was performed. (c) qPCR analysis for CD44, CD133 and L1CAM genes in adherent cells versus...

Additional file 4 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 4: Figure S4. Knockdown of LAMC2 does not affect cell growth. (a) Western blot analysis of LAMC2 in sh empty and LAMC2 knockdown cells. Parallel β-ACTIN immunoblotting was performed. (b) qPCR analysis for LAMC2 and CD44 gene expression in sh empty and LAMC2 knockdown cells. Data are normalized to GAPDH and are presented as fold change in gene expression relative to sh empty. (c) Representative images of sh empty and LAMC2 knockdown cells...

Additional file 6 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 6: Figure S6. Knockdown of LAMC2 affects tumorigenicity. (a) Representative images from a gelatin degradation assay of sh empty and LAMC2 knockdown cells. Nuclei were stained with Hoechst 33342 (blue), green represents actin (Alexa Fluor™ 488 Phalloidin) and red illustrates gelatin (Rodhamine). The white dashed line circles indicate the areas of degradation. (b) Degradation potential of sh empty and LAMC2 knockdown cells. (c) qPCR analysis for EMT genes in sh empty and LAMC2...

Additional file 7 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 7: Figure S7. Generation of LAMC2-EGFP knock-in human PDAC cells. (a) Flow cytometry for IRFP in PDAC cells 48 hours post-nucleofection. All cytometry gates were established based on isotype controls. (b) Flow cytometry for EGFP in PDAC cells 20 days post-nucleofection. All cytometry gates were established based on isotype controls. (c) PCR gDNA specific integration analysis. The positions of primers are indicated by arrows. (d) FACS profiles showing the expression of EGFP in...

Additional file 5 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 5: Figure S5. Loss of LAMC2 reduces stemness. (a) Flow cytometry for apoptotic cells as determined by AnnexinV/PI staining in control and LAMC2 knockdown cells. (b) Flow cytometry quantification of CD44 in sh empty and LAMC2 knockdown cells. (c) qPCR analysis of CD133 in sh empty and LAMC2 knockdown cells. Data are normalized to GAPDH and are presented as fold change in gene expression relative to sh empty. (d) Flow cytometry analysis of...

Additional file 9 of LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida, Eduard Batlle, Annachiara De Luca & Enza Lonardo
Additional file 9: Figure S9. Global gene expression profiles of LAMC2-EGFP+ and EGFP--derived tumors. Heat map of differentially expressed genes in EGFP+ and EGFP- cells isolated from tumors.

Registration Year

  • 2023
    12
  • 2022
    24
  • 2018
    2

Resource Types

  • Text
    38

Affiliations

  • Institute for Research in Biomedicine
    38
  • Institució Catalana de Recerca i Estudis Avançats
    38
  • University of Padua
    32
  • Shanghai Jiao Tong University
    32
  • Venetian Institute of Molecular Medicine
    15
  • Alberto Sols Biomedical Research Institute
    15
  • Instituto Ramón y Cajal de Investigación Sanitaria
    15
  • National Research Council
    15
  • Barcelona Supercomputing Center
    13
  • Qinghai University Affiliated Hospital
    12